Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL3935711 | 0.94 | AOC3 (0.67) | AOC3MAOB | |
| Carbamic Acid SCHEMBL3934857 | 0.92 | AOC3 (0.61) | AOC3MAOB | |
| SCHEMBL4291906 | 0.88 | AOC3 (0.67) | AOC3MAOB | |
| Carbamic Acid SCHEMBL4887529 | 0.88 | AOC3 (0.51) | AOC3MAOB | |
| Carbamic Acid SCHEMBL4869434 | 0.88 | AOC3 (0.65) | AOC3MAOB | |
| Carbamic Acid SCHEMBL4874668 | 0.87 | AOC3 (0.66) | AOC3MAOB | |
| Carbamic Acid SCHEMBL3936159 | 0.86 | AOC3 (0.67) | AOC3MAOB | |
| Carbamic Acid SCHEMBL4881050 | 0.84 | AOC3 (0.49) | AOC3MAOB | |
| Carbamic Acid SCHEMBL4888141 | 0.82 | AOC3 (0.51) | AOC3MAOB | |
| Carbamic Acid SCHEMBL3932678 | 0.82 | AOC3 (0.65) | AOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885MAOB 923/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885MAOB 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.